Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks

被引：0

作者：

G. Bussone

G.C. Manzoni

P. Cortelli

M. Roncolato

L. Fabbri

C. Benassuti

机构：

[1] C. Besta National Neurological Institute,

[2] Milan,undefined

[3] Italy,undefined

[4] Neurology Department,undefined

[5] Parma,undefined

[6] Italy,undefined

[7] Neurology Department,undefined

[8] Bologna University,undefined

[9] Bologna,undefined

[10] Italy,undefined

[11] Glaxo Wellcome Medicines Research Centre,undefined

[12] Neurology and Psychiatry Medical Department,undefined

[13] Via Fleming 4,undefined

[14] I-37100 Verona,undefined

[15] Italy,undefined

来源：

Neurological Sciences | 2000年 / 21卷

关键词：

Key words Migraine; Sumatriptan; Efficacy; Safety;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

This cross-over, double blind, randomized, multicentre study evaluated the consistency of efficacy and safety of oral sumatriptan in 233 migraneurs. The patients received 50 mg oral sumatriptan or placebo for the treatment of 12 migraine attacks. Within each group of 4 attacks, three were treated with sumatriptan and one with placebo, according to a randomization list. Over all the attacks, the efficacy rate was statistically significant for sumatriptan against placebo at 2 or 4 hours (2 hours: sumatriptan 60%, PLO 38%, p<0.001; 4 hours sumatriptan 79%, PLO 47%, p<0.001). Oral sumatriptan was similarly effective at relieving the associated symptoms and at reducing clinical disability in most attacks. The incidence of adverse events did not differ between treatment groups. All the events recorded were mild to moderate as intensity and resolved spontaneously.

引用

页码：272 / 278

页数：6